ARCT vs DXCM · rev $5.0M vs P/E 63, rev $2.50B
Arcturus Therapeutics Holdings Inc (ARCT) versus DexCom Inc (DXCM) — a side-by-side from cached financials, not a winner call.
Arcturus Therapeutics Holdings Inc (ARCT) is a biotechnology company listed on US.
DexCom Inc (DXCM) is a medical devices company listed on US.
Latest reported ARCT revenue for 2026-06-30 was $5.0M. Net income was -$50.7M. ARCT currently screens at market cap $369.4M.
Latest reported DXCM revenue for 2026-06-30 was $2.50B. Net income was $448.6M. DXCM currently screens at market cap $32.84B and trailing P/E 62.5.
ARCT currently screens at market cap $369.4M. DXCM currently screens at market cap $32.84B and trailing P/E 62.5.
Not investment advice. Open the ARCT and DXCM stock pages for the full models.
Not investment advice.